Clinical trials: Breast Cancer (Early Breast Cancer)
Breast Cancer Early Stage Breast Cancer (Stage 1-3), Breast Neoplasm Female
Feasibility and Acceptibility of a Multi-site Trial of Time Restircted Eating During Chemotheraply for Breast Cancer.
This study is being done to better understand how time restricted eating (eating all food in an 8 hour window) can help a person receiving chemotherapy treatment for breast cancer, stages I-IV.
- Conditions
- Breast Cancer Early Stage Breast Cancer (Stage 1-3), Breast Neoplasm Female, Breast Cancer
- Trial name
- NCT07387445
- Testing
- Time restricted eating
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- University of Illinois Chicago
ER-positive Her2-negative Early Breast Cancer
Assessment of Genomic Test Impact on Shared Decision of Adjuvant Chemotherapy in ER-positive, Her2-negative Early Breast Cancer
The need/benefit of adjuvant chemotherapy could be negligible for a certain category of patient with newly diagnosed unilateral non metastatic breast cancer.
- Trial name
- OPTIGEN (NCT03080428)
- Testing
- Genomic test
- Sponsor
- UNICANCER
Breast Cancer
Clinical Trial Assessing the Safety of Neoadjuvant Palbociclib in Combination With Endocrine Therapy
Patients with estrogen receptor positive (ER+) and/or progesterone receptor positive (PR+) breast cancer do not achieve good responses with pre-operative chemotherapy.
- Trial name
- NCT05069038
- Testing
- Palbociclib 125mg
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- University of Nebraska
Early Detection of Cancer
National Breast and Thyroid Screening After a Treatment Received Against a Cancer During Childhood
The DENACAPST programme represents an important initiative to provide near nation-wide roll-out of an important cancer surveillance program for childhood cancer survivors.
- Trial name
- DENACAPST (NCT03183401)
- Where
- France
- Volunteers
- 2,000 people
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Breast Cancer, Ovarian Function
Protection of Ovarian Function With Goserelin Acetate in Premenopausal Early Breast Cancer Patients With Chemotherapy
Primary objective of this study is to determine the effectiveness of goserelin acetate (Zoladex) in preserving ovarian function in premenopausal women undergoing adjuvant chemotherapy for primary invasive breast cancer by…
- Trial name
- PROOF (NCT00888082)
- Testing
- Goserelin acetate
- Where
- 3 sites in Turkey (Türkiye)
- Volunteers
- 102 people
- Sponsor
- AstraZeneca
Breast Cancer
Efficacy of Nab-PHP Versus TCbHP in Neoadjuvant Therapy for HER2-positive Early Breast Cancer
The aim of this study is to evaluate the efficacy of nab-paclitaxel (on days 1 and 8 of a 21-day cycle) compared to the standard regimen of docetaxel plus carboplatin, both combined with trastuzumab and pertuzumab, as neoadjuvant…
- Trial name
- NCT07057427
- Testing
- Nab paclitaxel, Docetaxel and Carboplatin, Trastuzumab + Pertuzumab
- Where
- China
- Volunteers
- 812 people
- Sponsor
- Henan Cancer Hospital
Breast Cancer, HER2-negative Breast Cancer
CLEAR-B: Cancer Landscape - Early Adjuvant Retrospective Registry - Breast Cancer
This is a non-interventional retrospective cohort study of premenopausal patients with HR+/HER2- breast cancer who are treated in the adjuvant setting with either Tamoxifen, Tamoxifen + Ovarial Function Suppression or Aromatase…
- Conditions
- Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Breast Carcinoma
- Trial name
- CLEAR-B (NCT05870813)
- Where
- Germany
- Volunteers
- 3,000 people
- Sponsor
- Institut fuer Frauengesundheit
Locally Advanced Breast Cancer, Hormone Receptor Positive，HER2-negative Breast Cancer
Select the Appropriate Population for Adding CDK4/6i to Neoadjuvant Endocrine Therapy
Select the appropriate population for adding CDK4/6 inhibitors therapy in high risk early HR+/HER2-breast cancer based on molecular detection
- Trial name
- NCT05809024
- Testing
- letrozole
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Yongsheng Wang
Breast Cancer Early Stage Breast Cancer (Stage 1-3)
Reflects the Intervention (AI Chatbot)
The goal of this clinical trial is to investigate the impact of an AI-powered chatbot intervention on improving knowledge, attitudes, and empowerment in breast cancer patients.
- Trial name
- BC-CHAT (NCT06943911)
- Testing
- AI Chatbot for Breast Cancer Patient Education and Empowerment
- Where
- Egypt
- Volunteers
- 122 people, healthy volunteers welcome
- Sponsor
- Mostafa Shaban
HER2-positive Early Breast Cancer
Neoadjuvant Trastuzumab-rezetecan Plus Pertuzumab or Nab-Paclitaxel, Carboplatin, Trastuzumab, and Pyrotinib After Suboptimal Response to Neoadjuvant Dual HER2-Targeted Therapy Combined With Chemotherapy in HER2-Positive Early Breast Cancer
This prospective, response-guided phase II study investigates individualized neoadjuvant treatment strategies for patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer.
- Trial name
- TAYLOR (NCT07340398)
- Testing
- Nab paclitaxel, Carboplatin, Trastuzumab
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Breast Cancer
Low-dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor-negative Early Breast Cancer
This randomized, phase III trial was designed to test the efficacy of a low-dose chemotherapy-maintenance regimen, hypothesized to have anti-angiogenic activity, administered following standard chemotherapy in patients with early…
- Trial name
- 22-00 (NCT00022516)
- Testing
- Cyclophosphamide, Methotrexate
- Where
- 36 sites in Australia, Belgium and 9 more
- Volunteers
- 1,086 people
- Sponsor
- ETOP IBCSG Partners Foundation
Breast Cancer
Abraxane Combined With Xeloda as Neo-Adjuvant Chemotherapy in Early Breast Cancer
Some studies have demonstrated the efficacy of Abraxane in treating breast cancer in both adjuvant and metastatic settings. Few data is available on Abraxane in neoadjuvant treatment for breast cancer.
- Trial name
- NCT03647514
- Testing
- Abraxane, Xeloda
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Zhejiang Cancer Hospital
Breast Cancer
Self-efficacy Coaching for Women With Breast Cancer
This is an open, prospective, multi-center, interventional study to evaluate the benefit and efficacy of individualized self-efficacy coaching for women with high-risk early breast cancer.
- Trial name
- SECOM-PSWE (NCT03478384)
- Testing
- Patient coaching
- Where
- 6 sites in Switzerland
- Volunteers
- 46 people
- Sponsor
- Stiftung Patientenkompetenz
Ductal Breast Carcinoma in Situ, Invasive Ductal Breast Carcinoma
Caloric Restriction in Treating Patients With Stage 0-I Breast Cancer Undergoing Surgery and Radiation Therapy
This pilot clinical trial studies caloric restriction in patients with stage 0-I breast cancer during surgery and radiation therapy. Reducing caloric intake may prevent disease progression in patients with breast cancer.
- Conditions
- Ductal Breast Carcinoma in Situ, Invasive Ductal Breast Carcinoma, Invasive Lobular Breast Carcinoma, Lobular Breast Carcinoma in Situ
- Trial name
- CAREFOR (NCT01819233)
- Testing
- Behavioral dietary intervention, Therapeutic conventional surgery, Radiation therapy
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Breast Cancer, Invasive Carcinoma of Breast
5 vs. 9-day Course of Whole Breast Radiotherapy With Boost for Early-stage Breast Cancer
The goal of this study is to evaluate 5 days vs. 9 days of whole breast radiation.
- Conditions
- Breast Cancer, Invasive Carcinoma of Breast, Ductal Breast Carcinoma in Situ
- Trial name
- FAST NOVEMBER (NCT06961955)
- Testing
- Radiation Therapy
- Where
- United States
- Volunteers
- 144 people
- Sponsor
- University of Utah
Breast Neoplasms
Docetaxel Followed by Capecitabine Versus Concomitant Docetaxel/Capecitabine for Early Stage Breast Cancer
The purpose of this study is to identify new chemotherapy treatment regimens with better response rates and to find out if the combination of docetaxel and capecitabine can shrink the size of breast tumors and preserve the breast.
- Trial name
- NCT00415285
- Testing
- Docetaxel, Capecitabine, Docetaxel/Capecitabine
- Where
- 3 sites in United States
- Volunteers
- 100 people
- Sponsor
- Georgia Center for Oncology Research & Education
Triple-Negative Breast Cancer
Low-dose Apatinib Combined With Neoadjuvant Chemotherapy in the Treatment of Early Triple Negative Breast Cancer
Triple-negative breast cancer (TNBC) is a special type of breast cancer, endocrine therapy and targeted therapy are completely ineffective, chemotherapy is currently the only effective treatment.
- Trial name
- LANCET (NCT03243838)
- Testing
- Apatinib
- Where
- 2 sites in China
- Volunteers
- 31 people
- Sponsor
- Guangdong Provincial People's Hospital
Adenocarcinoma of the Breast, Breast Cancer
A Study of Cyclophosphamide, Methotrexate, Fluorouracil (CMF) for People With Breast Cancer
The purpose of this study is to find out if it is practical (feasible) to give dose-dense CMF (cyclophosphamide, methotrexate, and fluorouracil) in two standard chemotherapy regimens in people with breast cancer, age 70 and older.
- Conditions
- Adenocarcinoma of the Breast, Breast Cancer, Triple Negative Breast Cancer
- Trial name
- NCT07768436
- Testing
- CMF Regimen, Paclitaxel
- Where
- 7 sites in United States
- Volunteers
- 76 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Breast Conserving Surgery, Endoscopic Surgery
Single Port Endoscopic Breast Conserving Surgery
The center plans to carry out a prospective clinical study of single hole total endoscopic breast conserving surgery for early breast cancer compared with open breast conserving surgery, to provide high-level evidence-based…
- Trial name
- NCT06593132
- Testing
- endoscopic breast conserving surgery
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Ren,Yu
Breast Cancer
Multi-catheter High Dose Rate (HDR) Breast Brachytherapy
Breast conservation therapy (BCT) is now widely accepted as a treatment option for most women with Stage I and II invasive breast cancer and most patients with ductal carcinoma in situ (DCIS).
- Trial name
- NCT00214149
- Testing
- brachytherapy
- Where
- United States
- Volunteers
- 127 people
- Sponsor
- University of Wisconsin, Madison
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.